Cytokinetics (NASDAQ:CYTK) Announces Earnings Results

Cytokinetics (NASDAQ:CYTK) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13, FiscalAI reports. The business had revenue of $28.62 million during the quarter, compared to the consensus estimate of $17.59 million. During the same period in the prior year, the firm earned ($1.12) EPS. The business’s revenue for the quarter was down 57.1% on a year-over-year basis.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO launch momentum exceeded expectations, with $25.3 million in Q2 net product revenue, 1,500 patients dispensed, more than 700 U.S. prescribers, and greater than 40% exit share of new-to-brand prescriptions. Medicare coverage reached nearly 90% parity, while commercial coverage exceeded 50%.
• Aficamten’s ACACIA-HCM Phase III trial met both primary endpoints in non-obstructive HCM, improving KCCQ scores and peak VO2 without new safety signals. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, potentially expanding MYQORZO to a substantially larger patient population.
• International expansion progressed with the German launch, U.K. marketing authorization and NICE reimbursement guidance, and reimbursement approval in the Netherlands. The company expects a U.K. launch later this year, followed by additional European launches through 2027.
• Cytokinetics ended Q2 with approximately $1.7 billion in cash and investments after raising $760 million, providing funding for commercialization and pipeline development. However, the net loss widened to $198.8 million, and full-year combined R&D and SG&A expense guidance was increased to $860 million–$890 million.
• The broader specialty-cardiology pipeline continued advancing, with COMET-HF enrolling more than one-third of patients, AMBER-HFpEF expected to complete its first cohort in the second half of 2026, and the adolescent cohort of CEDAR-HCM enrolling ahead of schedule.

Cytokinetics Price Performance

Shares of CYTK stock traded down $4.61 on Friday, reaching $76.76. 3,604,418 shares of the company were exchanged, compared to its average volume of 1,732,641. The company has a market cap of $9.55 billion, a price-to-earnings ratio of -10.63 and a beta of 0.38. The company has a 50-day moving average of $78.91 and a 200-day moving average of $70.90. Cytokinetics has a one year low of $32.89 and a one year high of $88.31.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. UBS Group upgraded Cytokinetics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $69.00 to $115.00 in a research note on Monday, June 29th. Wells Fargo & Company raised their price objective on Cytokinetics from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Mizuho lifted their price objective on Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, June 24th. HC Wainwright upped their target price on Cytokinetics from $136.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Truist Financial set a $106.00 target price on Cytokinetics in a report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.85.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Insider Transactions at Cytokinetics

In related news, EVP Andrew Callos sold 14,000 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total transaction of $1,118,320.00. Following the transaction, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,677,373.40. This represents a 19.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sung Lee sold 1,112 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $87.79, for a total value of $97,622.48. Following the completion of the transaction, the executive vice president owned 63,221 shares in the company, valued at approximately $5,550,171.59. The trade was a 1.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 115,179 shares of company stock valued at $9,126,054. 2.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Cytokinetics

Hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 673 shares during the period. Kemnay Advisory Services Inc. bought a new position in Cytokinetics during the fourth quarter valued at approximately $27,000. Kestra Advisory Services LLC bought a new stake in shares of Cytokinetics in the 4th quarter worth approximately $29,000. Quarry LP bought a new stake in shares of Cytokinetics in the 3rd quarter worth approximately $30,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Cytokinetics in the 3rd quarter valued at $32,000.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.